{"id":"metformin-alogliptin-oral-product","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Nasopharyngitis"},{"rate":"<1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases gluconeogenesis and enhances peripheral glucose uptake, primarily in muscle and adipose tissue. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the degradation of GLP-1 and GIP, thereby prolonging their action to stimulate glucose-dependent insulin secretion and suppress glucagon. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while alogliptin inhibits DPP-4 to increase incretin levels and stimulate insulin secretion in response to glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:22.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT02068443","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Type 2 Diabetes Mellitus","enrollment":374},{"nctId":"NCT03555565","phase":"","title":"Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-28","conditions":"Type 2 Diabetes Mellitus","enrollment":1026},{"nctId":"NCT02856113","phase":"PHASE3","title":"Phase 3 Alogliptin Pediatric Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-10-14","conditions":"Diabetes Mellitus, Type 2","enrollment":152},{"nctId":"NCT03794336","phase":"PHASE4","title":"Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-06-29","conditions":"Type 2 Diabetes Mellitus","enrollment":1293},{"nctId":"NCT04392557","phase":"PHASE4","title":"Anti-inflammatory Status in DM2 Treated Patients","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT02989649","phase":"","title":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":593},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT01890122","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-09","conditions":"Diabetes Mellitus","enrollment":647},{"nctId":"NCT02508168","phase":"PHASE1","title":"Phase 1 Bioavailability Study of SYR-322MET","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT02798172","phase":"NA","title":"The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"Fourth People's Hospital of Shenyang","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT00856284","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":2639},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT01023581","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":784},{"nctId":"NCT01289119","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01318135","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":576},{"nctId":"NCT00286442","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-03","conditions":"Diabetes Mellitus","enrollment":527},{"nctId":"NCT01318109","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":288},{"nctId":"NCT00755846","phase":"PHASE2","title":"Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-03","conditions":"Diabetes Mellitus","enrollment":265}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Metformin / alogliptin Oral Product","genericName":"Metformin / alogliptin Oral Product","companyName":"University of Catanzaro","companyId":"university-of-catanzaro","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while alogliptin inhibits DPP-4 to increase incretin levels and stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}